{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:32:23Z","timestamp":1780605143197,"version":"3.54.1"},"reference-count":43,"publisher":"Impact Journals, LLC","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2020,4,14]]},"DOI":"10.18632\/oncotarget.27536","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T13:25:18Z","timestamp":1586870718000},"page":"1334-1343","source":"Crossref","is-referenced-by-count":30,"title":["A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent\/recurrent loco-regional or metastatic anal cancer"],"prefix":"10.18632","volume":"11","author":[{"given":"Cathy","family":"Eng","sequence":"first","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Fakih","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manik","family":"Amin","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van","family":"Morris","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard S.","family":"Hochster","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute, New Brunswick, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Boland","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Uronis","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2020,4,14]]},"reference":[{"key":"1","unstructured":"National Cancer Institute. Cancer Stat Facts: Anal Cancer."},{"key":"2","unstructured":"American Cancer\u2014Society. Key Statistics for Anal Cancer."},{"key":"3","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1200\/JCO.2012.45.2524","article-title":"Changing patterns of anal canal carcinoma in the United States","volume":"31","author":"Lai","year":"2013","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Murray","year":"1996","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups","volume":"15","author":"Pierart","year":"1997","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/07357900600815208","article-title":"Anal cancer: current and future methodology","volume":"24","author":"Eng","year":"2006","journal-title":"Cancer Invest"},{"key":"7","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ijrobp.2006.12.052","article-title":"Predictors and patterns of recurrence after definitive chemoradiation for anal cancer","volume":"68","author":"Crane","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"8","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3748\/wjg.v21.i8.2294","article-title":"Anal cancer treatment: current status and future perspectives","volume":"21","author":"Nasr","year":"2015","journal-title":"World J Gastroenterol"},{"key":"9","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study","volume":"19","author":"Ghiringhelli","year":"2018","journal-title":"Lancet Oncol"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Rao, Sclafani, Eng, Guren, Adams, Benson, Sebag-Montefiore, Segelov, Bryant, Peckitt, Roy, Seymour, Welch, et al. Interaact: A Multicentre Open Label Randomised Phase Ii Advanced Anal Cancer Trial Of Cisplatin (CDDP) Plus 5-Fluorouracil (5-FU) vs Carboplatin (C) Plus Weekly Paclitaxel (P) In Patients (Pts) With Inoperable Locally Recurrent (ILR) or Metastatic Treatment Na\u00efve Disease - An International Rare Cancers Initiative (IRCI) Trial. ESMO 2018 Congress. 2018.","DOI":"10.1093\/annonc\/mdy424.022"},{"key":"11","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1002\/ijc.24215","article-title":"Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions","volume":"124","author":"Smith","year":"2009","journal-title":"Int J Cancer"},{"key":"12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"McDougall","year":"2004","journal-title":"Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.2015-0091","article-title":"Clinicopathologic Features Associated With Human Papillomavirus\/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal","volume":"20","author":"Eng","year":"2015","journal-title":"Oncologist"},{"key":"14","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM199711063371904","article-title":"Sexually transmitted infection as a cause of anal cancer","volume":"337","author":"Melbye","year":"1997","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"publisher","first-page":"9094","DOI":"10.1128\/MCB.23.24.9094-9103.2003","article-title":"Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7","volume":"23","author":"Lambert","year":"2003","journal-title":"Mol Cell Biol"},{"key":"16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1126\/science.2157286","article-title":"Association of human papillomavirus types 16 and 18 E6 proteins with p53","volume":"248","author":"Howley","year":"1990","journal-title":"Science"},{"key":"17","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","article-title":"The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53","volume":"63","author":"Howley","year":"1990","journal-title":"Cell"},{"key":"18","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","article-title":"Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6","volume":"64","author":"van der Burg","year":"2004","journal-title":"Cancer Res"},{"key":"19","first-page":"636","article-title":"Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter","volume":"63","author":"van der Burg","year":"2003","journal-title":"Cancer Res"},{"key":"20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Vence","year":"2017","journal-title":"Lancet Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Saraf","year":"2017","journal-title":"Ann Oncol"},{"key":"22","unstructured":"National Comprehensive Cancer Network. NCCN Guidelins Version 1. Anal Carcinoma. 2018."},{"key":"23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40661-017-0046-9","article-title":"Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy","volume":"4","author":"Safran","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fcimb.2014.00051","article-title":"Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy","volume":"4","author":"Paterson","year":"2014","journal-title":"Front Cell Infect Microbiol"},{"key":"25","doi-asserted-by":"publisher","first-page":"e25752","DOI":"10.4161\/onci.25752","article-title":"Interferon gamma-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with Listeria monocytogenes","volume":"2","author":"Paterson","year":"2013","journal-title":"OncoImmunology"},{"key":"26","first-page":"2","article-title":"Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer","volume":"7","author":"Paterson","year":"2007","journal-title":"Cancer Immun"},{"key":"27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00262-004-0610-0","article-title":"Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors","volume":"54","author":"Paterson","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"28","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.4049\/jimmunol.172.10.6030","article-title":"The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function","volume":"172","author":"Paterson","year":"2004","journal-title":"J Immunol"},{"key":"29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/00002371-200409000-00002","article-title":"CD4+CD25+ regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector","volume":"27","author":"Paterson","year":"2004","journal-title":"J Immunother"},{"key":"30","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.4049\/jimmunol.167.11.6471","article-title":"Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16","volume":"167","author":"Paterson","year":"2001","journal-title":"J Immunol"},{"key":"31","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1016\/j.vaccine.2008.07.036","article-title":"Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors","volume":"26","author":"Paterson","year":"2008","journal-title":"Vaccine"},{"key":"32","doi-asserted-by":"publisher","first-page":"8066","DOI":"10.1158\/0008-5472.CAN-08-0287","article-title":"Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature","volume":"68","author":"Paterson","year":"2008","journal-title":"Cancer Res"},{"key":"33","article-title":"Treatment with Lm-LLO immunotherapies lead to decreased Tregs and MDSC in the tumor microenvironment (165.12)","volume":"188","author":"Wallecha","year":"2012","journal-title":"J Immunol"},{"key":"34","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/CJI.0000000000000000","article-title":"Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment","volume":"36","author":"Malinina","year":"2013","journal-title":"J Immunother"},{"key":"35","unstructured":"Becker. Advaxis Provides Clinical Update For Phase 1\/2 Trial Of ADXS-HPV Immunotherapy Product Candidate In Anal Cancer. ADVAXIS (ed). 2014. https:\/\/ir.advaxis.com."},{"key":"36","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","article-title":"The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix","volume":"27","author":"Rothman","year":"2009","journal-title":"Vaccine"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.e14580","article-title":"Phase I study evaluating high-dose treatment with ADXS11-001, a Listeria monocytogenes-listeriolysin O (Lm-LLO) immunotherapy, in women with cervical cancer","volume":"34","author":"Khleif","year":"2016","journal-title":"J Clin Oncol"},{"key":"38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Dodd","year":"2009","journal-title":"Eur J Cancer"},{"key":"39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/105294199277860","article-title":"The International Conference on Harmonization Good Clinical Practice guideline","volume":"6","author":"Dixon","year":"1998","journal-title":"Qual Assur"},{"key":"40","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Hodi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"41","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03."},{"key":"42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1081\/BIP-100101181","article-title":"Multinomial phase II cancer trials incorporating response and early progression","volume":"9","author":"Eisenhauer","year":"1999","journal-title":"J Biopharm Stat"},{"key":"43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","article-title":"A Confidence Interval for the Median Survival Time","volume":"38","author":"Crowley","year":"1982","journal-title":"Biometrics"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T20:55:03Z","timestamp":1591390503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":43,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,4,14]]}},"alternative-id":["27536","32341753"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27536","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,14]]}}}